AngioDynamics loses patent infringement jury verdict to Bard on port products

ANGIODYNAMICS INC

Jury verdict found AngioDynamics' implantable port products infringe certain Bard patents (Nov 22, 2022).
Damages were bifurcated and not determined by jury; separate proceeding required.
Company strongly disagrees with verdict, believes it is unsupported, and plans post-trial motions and appeals.
Equitable issues and patent eligibility issues remain to be decided by the judge.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.